Fulvestrant can therefore be considered as alternative therapy to anastrozole or exemestane in postmenopausal women with locally advanced or metastatic breast cancer that has recurred on prior adjuvant endocrine therapy or progressed on prior endocrine therapy for advanced disease .
A systematic review was undertaken to examine all available evidence to develop and support clinical recommendations regarding the use of fulvestrant ( Faslodex ® ) as systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women .
Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality.
The r and omized , double-blind , placebo-controlled trial is the optimum method for clinical evaluation of new treatments , as assessed by clinicians and statisticians . However , if a known st and ard of therapy exists , it may be difficult to prove that a new therapy is superior . Equivalence and noninferiority clinical trial design s are now frequently utilized in clinical medical research . This article review s the statistical differences between superiority , equivalence , and noninferiority design schemes , which pose specific ethical questions and have important implication s for interpretation and clinical application of trial results . A guideline is proposed as a st and ard approach for reporting to facilitate qualitative assessment of the methodology of these trials
Fulvestrant can therefore be considered as alternative therapy to anastrozole or exemestane in postmenopausal women with locally advanced or metastatic breast cancer that has recurred on prior adjuvant endocrine therapy or progressed on prior endocrine therapy for advanced disease .
A systematic review was undertaken to examine all available evidence to develop and support clinical recommendations regarding the use of fulvestrant ( Faslodex ® ) as systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women .